AI Article Synopsis
- This study investigates the altered gene expression in gastric cancer patients, highlighting 590 differentially expressed genes compared to healthy controls.
- Among these genes, one shows promise as a prognostic biomarker, indicating its potential to predict patient outcomes.
- Additionally, patients with low expression levels of this gene may respond better to specific chemotherapeutic agents, helping to tailor treatment strategies for gastric cancer.
Article Abstract
The altered expression of in patients with gastric cancer has been reported frequently, yet its correlation to prognosis and chemotherapy needs to be unveiled. In combination of the gene expression data retrieved from TCGA database and bioinformatic analysis, this study discovered 590 differentially expressed genes in the cancerous biopsies isolated from gastric patients, compared with controls. Among which, exhibited great potential to serve as a prognostic biomarker for gastric patients; furthermore, patients with low expression of could be more sensitive to these 9 chemotherapeutic agents: A-770041, AMG-706, ATRA, BEZ235, bortezomib, CGP60474, dasatinib, HG-64-1, and pazopanib, rather than the other chemotherapeutic agents. This study helps the improvement of evaluating the prognosis of gastric cancer patients, and would help optimize chemotherapeutic strategies in consideration of the expression of .
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886469 | PMC |
| http://dx.doi.org/10.1155/2023/2623317 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!